TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
September 17, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
RNAi Market and Technologies Industry Report 2024, with Company Profiles of Major Players including Alnylam Pharmaceuticals, Novartis, Thermo Fisher Scientific and Revvity
August 23, 2024 04:02 ET
|
Research and Markets
Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "RNAi Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for RNAi technology is estimated to...
ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
July 30, 2024 09:05 ET
|
ADARx Pharmaceuticals
ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
June 12, 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for...
Phio Pharmaceuticals Secures New Investor
May 17, 2024 09:00 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
May 16, 2024 08:00 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
May 15, 2024 13:00 ET
|
Phio Pharmaceuticals Corp.
-PH-762 is Phio’s lead product candidate -Screening on the next cohort is on-going MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage...
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
May 09, 2024 17:25 ET
|
Phio Pharmaceuticals Corp.
–Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 –Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) --...
Global RNAi Therapeutics Market Analysis Report 2024-2028: Progress in Collaborations & Associated Deals Bodes Well for the Sector
May 01, 2024 09:16 ET
|
Research and Markets
Dublin, May 01, 2024 (GLOBE NEWSWIRE) -- The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19...
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
April 30, 2024 07:30 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...